Xilio Therapeutics, INC. (XLO) — DEF 14A Filings
All DEF 14A filings from Xilio Therapeutics, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Xilio Seeks Shareholder Nod for Option Repricing, New Stock Plan
— Oct 20, 2025 Risk: medium
Xilio Therapeutics, Inc. (XLO) is holding a special meeting on November 21, 2025, to seek stockholder approval for two critical compensation-related proposals: -
Xilio Therapeutics Files Definitive Proxy Statement
— Apr 28, 2025 Risk: low
Xilio Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting on June 10, 2025. The company, incorporated in Delaware -
Xilio Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13
— Apr 25, 2024 Risk: low
Xilio Therapeutics, Inc. (XLO) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Xilio Therapeutics will hold its 2024 Annual Meeting of Stockho
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX